Nausea and vomiting are among the most common and feared side-effects of cancer chemotherapy. In particular, cisplatin has been recognised for its high emetogenic potential (Von Hoff et al., 1979) . The quality of life of the cancer patients and their compliance with treatment, which continues over several courses, depend on the effective management of these side-effects. It is very important to achieve good control during the first course of chemotherapy in order to avoid anticipatory nausea and vomiting before the next or subsequent treatments.
In recent years significant advances in control of acute emesis during the initial 24 h after cisplatin administration have been made, using high-dose metoclopramide (Gralla et al., 1981) , dexamethasone (Kris et al., 1983 (Kris et al., , 1985a and 5-hydroxytryptamine (5-HT3) antagonists (Cunningham et al., 1987; Hainsworth and Hesketh, 1992; Jantunen et al., 1993; Joss et al., 1993) . However, the success obtained in the prevention of acute emesis has not been extended to control of delayed emesis induced by cisplatin. Delayed emesis appearing beyond the first 24 h after chemotherapy remains a significant cause of treatment-related morbidity and patient refusal of further chemotherapy despite the use of various antiemetic drugs, including corticosteroids, major tranquilisers, and 5-HT3 antagonists. The treatment of choice for delayed emesis still remains to be established; in fact, only a few randomised trials have been carried out. The factors associated with delayed emesis have also not been sufficiently studied. Therefore, we carried out an open randomised study to compare the efficacy and safety of a combination of granisetron, dexamethasone and prochlorperazine with granisetron alone in the prophylaxis of delayed emesis, and to define the factors associated with delayed symptoms induced by cisplatin in patients who had not previously received cisplatin-based chemotherapy.
Patients and methods

Patient selection
Eligibility criteria for entry into the study were as follows: (1) Acute nausea Patterns and the severity of acute nausea between the two groups did not differ. The rates of no or mild nausea observed during the first 24 h were 69% in a combination of granisetron, dexamethasone and prochlorperazine, and 54% in a granisetron-alone group (P = 0.3267).
Acute emetic episodes The rates of complete emetic control were 51 % in arm 1 and 66% in the 2 (P = 0.3318). The rates of complete plus major emetic control were similar, with 72% in treatment arm 1 vs 77% in treatment arm 2 on day 1 (P = 0.7845). A variety of factors were analysed to determine their impact on the control of acute emesis. Gender and a habitual high alcohol intake ( > 75 g per day) were significant for controlling acute emesis and P-values were 0.0043 and 0.0161 respectively. A multivariate analysis showed that gender was the only significant factor for control of acute emesis among six factors (P = 0.0044).
Delayed nausea
The rates of no or mild nausea were 43% in arm 1 and 74% in arm 2 on day 2 (P = 0.0153), and on day 3, 54% in arm 1 and 72% in arm 2 (P = 0.2162). Three patients only experienced most severe nausea after day 3. overall control rate, but significant for complete control (P = 0.0077). A habitual high alcohol intake and good control of acute emesis were significant factors, indicating a good protection from delayed emesis. In this trial, all habitual high alcohol users were men. When patients were divided into the three groups of women, men without a habitual high alcohol intake and men with a habitual high alcohol intake, the control rates were 50%, 61% and 92% respectively (P = 0.0482).
Multivariate logistic regression analysis of variables, including age, performance status, gender, concurrent chest irradiation, presence of non-cisplatin containing prior therapy, level of acute emesis and habitual alcohol intake for protection from delayed emesis was carried out (Table III) . Treatment arm (P = 0.0101) was only of independent prognostic significance for attaining a major control of delayed emetic episodes. Safety There were no differences in toxicity during the trial between the two arms. Headache is known to be the most common adverse event in patients receiving 5-HT3-blockers. In our study, five patients (7%) experienced grade 1 headache, but needed no treatment. Six patients (9%) experienced constipation on day 1. Dexamethasone plus prochlorperazine for control of delayed emesis was extremely well tolerated by The 5-HT3 antagonists have improved the treatment of acute cisplatin-induced nausea and vomiting. Chevallier (1993) reported the trial comparing granisetron alone with high-dose metoclopramide plus dexamethasone, showing that no significant differences were detected between the two groups in the incidence of acute emesis induced by cisplatin. The incidence of delayed emesis induced by cisplatin was reported to be 50-70% when 5-HT3 antagonists were used to control acute emesis (Gandara et al., 1992; Italian Group for Antiemetic Research, 1993; Kaizer et al., 1994 (Table II) . There was a statistically significant 26% difference in the complete and major control rates between the two arms.
In agreement with other investigators (Kris et al., 1985b (Kris et al., , 1989 Gandara et al., 1992) , the highest incidence of delayed emesis was observed on day 2 after cisplatin administration, and only three patients experienced first delayed emesis on day 4 or later in our study. Delayed emesis seems to become a smaller problem if it is well controlled on days 2 and 3. Therefore, every effort should be directed to obtaining perfect protection from both acute and delayed emesis on days I -3. Dose of cisplatin, control of acute emesis and gender have previously been reported as important determinants for delayed emesis (Kris et al., 1985a; Roila et al., 1991; Italian Group for Antiemetic Research 1994) . In this study, dose of cisplatin (80 mg m-2 or 100 mg mn-) was also not a significant factor. This may be because all patients received high-dose cisplatin (either dose level of 80 mg m-2 or 100 mg m-2) (Table II) . Treatment arm, habitual high alcohol intake and control of acute emesis were significant variables in univariate analysis. Multivariate analysis using logistic regression models revealed that treatment arm (arm 1 or arm 2) was the only important factor (P = 0.0101) ( Table  III) . A habitual high alcohol intake was the second, but did not reach statistical significance. The importance of complete control of acute emesis, which is often quoted as a significant determinant of subsequent antiemetic control, was not confirmed by multivariate analysis. This may be explained by different characteristics of population in this study, or by the relatively small number of patients, which provides only a low statistical power for detecting differences of moderate magnitude between the groups.
In conclusion, a combination of granisetron, dexamethasone and prochlorperazine was more effective than granisetron alone in protection from delayed emesis after high-dose cisplatin. Since 23% of patients treated with the combination regimen suffered from severe delayed emesis, further studies with other more effective combinations of antiemetics with different mechanisms of action are needed to improve results in this population.
